baltimore conference logo
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD: Case 2

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

EP. 1: Javier Pinilla-Ibarz, MD, PhD: Relapse Following Purine Analog Therapy

September 26th 2015

EP. 2: Javier Pinilla-Ibarz, MD, PhD: Treatment Options for Patients With Previously Treated CLL

September 26th 2015

EP. 3: Javier Pinilla-Ibarz, MD, PhD: Bendamustine/Rituximab Therapy

September 26th 2015

EP. 4: Javier Pinilla-Ibarz, MD, PhD: Options to Prolong Survival

September 26th 2015

EP. 5: Javier Pinilla-Ibarz, MD, PhD: Phase III Data to Support Usage of Bruton's TKIs

September 26th 2015

EP. 6: Paul Barr, MD: Treatment Options for Patients With Previously Treated CLL

September 26th 2015

EP. 7: Paul Barr, MD: Bendamustine/Rituximab Therapy

September 26th 2015

EP. 8: Paul Barr, MD: Options to Prolong Survival

September 26th 2015

EP. 9: Paul Barr, MD: Relapse Following Purine Analog Therapy

September 26th 2015

EP. 10: Paul Barr, MD: Phase III Data to Support Usage of Bruton's TKIs

September 26th 2015